The Combined Effect of Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors on Thyroid Function
Authors' conclusion
Thyroid dysfunction is a frequent adverse event in individuals treated with combination ICI+TKI therapy, with our data suggesting a rapid onset and higher incidence than previously seen with ICI or TKI therapy alone.
Study context
- Population
- Patients treated with combination ICI+TKI cancer therapy with pretreatment normal TSH, City of Hope Comprehensive Cancer Center, 2017–2023; median age 63.5 years
- Participants
- 106 patients
- Outcome
- Frequency, timing and severity of thyroid function test abnormalities during ICI+TKI therapy, and requirement for thyroid hormone replacement
- Follow-up
- Median 12.8 months (IQR 5.9-20.9)
Methodological detailssingle-centre
- Single-centre
Main finding
As reported in the abstract
Thyroid function abnormalities
ICI+TKI
63.2%
67 of 106
- Hyperthyroidism
- 11 (10.4%)
- Subclinical hypothyroidism (SCHypo)
- 42 (39.6%)
- Overt hypothyroidism
- 14 (13.2%)
- Median onset, hyperthyroidism
- 7 weeks (IQR 3.1-9.0)
- Median onset, SCHypo
- 8.0 weeks (IQR 3.0-19.0)
- Median onset, overt or worsening hypothyroidism
- 8.1 weeks (IQR 5.9-9.1)
Observational data: associations, not effects.
Original publication
The Combined Effect of Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors on Thyroid Function. Thyroid. Published 9 December 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →